4/18/2012 9:57:16 AM
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that data from the ASCEND-PD Phase III clinical study involving IPX066 will be presented in a Platform Presentation at the 64th Annual Meeting of the American Academy of Neurology in New Orleans, Louisiana, held from April 21 to April 28. IPX066 is an investigational, patented extended release capsule formulation of carbidopa-levodopa (CD-LD) intended for the treatment of idiopathic Parkinson’s disease. IPX066 is being developed in collaboration with GlaxoSmithKline (GSK) for territories countries outside the U.S. and Taiwan.
comments powered by